Ferguson Wellman Capital Management Inc. Has $10.16 Million Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Ferguson Wellman Capital Management Inc. reduced its stake in Thermo Fisher Scientific Inc. by 16.2% in Q2, selling 4,860 shares, leaving them with 25,059 shares valued at approximately $10.16 million.
• Thermo Fisher reported Q2 earnings of $5.36 per share, exceeding expectations, with a revenue of $10.86 billion, reflecting a 2.9% year-over-year increase.
• The company announced a quarterly dividend of $0.43 per share, representing a 0.4% yield, with the payout ratio currently at 9.95%.

Ferguson Wellman Capital Management Inc. decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 16.2% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 25,059 shares of the medical research company's stock after selling 4,860 shares during the quarter. Ferguson Wellman Capital Management Inc.'s holdings in Thermo Fisher Scientific were worth $10,160,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Bernard Wealth Management Corp. purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at about $25,000. CBIZ Investment Advisory Services LLC boosted its stake in shares of Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after acquiring an additional 33 shares during the last quarter. Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $30,000. Anderson Financial Strategies LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter worth $30,000. Finally, Keystone Global Partners LLC acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter worth about $31,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on TMO shares. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. HSBC reissued a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a research note on Friday, July 11th. Finally, Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $490.00 to $550.00 in a research report on Thursday, September 11th. Sixteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average price target of $588.35.

Insider Activity

In other news, CEO Marc N. Casper sold 400 shares of the stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares of the company's stock, valued at approximately $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Down 0.2%

Shares of TMO stock traded down $1.08 during trading on Friday, hitting $480.02. 4,241,401 shares of the company were exchanged, compared to its average volume of 1,433,914. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market capitalization of $181.26 billion, a price-to-earnings ratio of 27.76, a P/E/G ratio of 2.56 and a beta of 0.75. The business's 50-day simple moving average is $472.01 and its 200 day simple moving average is $449.50. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the prior year, the company posted $5.37 earnings per share. The firm's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.